Skip to content

Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy

Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02852018
Acronym
GENECHOC
Enrollment
1500
Registered
2016-08-02
Start date
2010-01-31
Completion date
2017-11-30
Last updated
2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy

Brief summary

The aim of this project is to identify common genetic polymorphisms associated with the occurrence of rhythmic events in patients with severe cardiomyopathy.

Interventions

GENETICIdentification of genetic polymorphisms

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients implanted for primary prevention, an implantable cardioverter defibrillator (ICD) single or double room, for severe cardiomyopathy (EF \<35%) * Patients with ischemic cardiomyopathy or idiopathic dilated cardiomyopathy.- Appropriate treatment group: patients who had a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation * Group no event patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive proper treatment during the follow up period of the study

Exclusion criteria

* Patients implanted with an ICD for primary prevention in the context of a family hereditary disease (long QT syndrome, Brugada syndrome, hypertrophic cardiomyopathy, ventricular tachycardia catecholergic right ventricular dysplasia ...). * Patients with left ventricular function greater than 35%. * Patients implanted with a defibrillator function resynchronization. * Patients minors, adults under guardianship and protected persons are eligible under this project.

Design outcomes

Primary

MeasureTime frame
Prevalence of polymorphisms pre-selected candidates (or by direct sequencing by High Resolution Melting).4 years
Identification of polymorphisms frequent (> 5% in the general population) by association study ( Genome Wide Association Study '(GWAS)) using genotyping technology broadband Axiom (Affymetrix).4 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026